Magazine Article | March 1, 2022

Why Biotechs Need A Practical Approach To Going Public

Source: Life Science Leader

By David Diamond

With the interest surrounding investment in the biotech field, many biotech companies are entering the public market significantly earlier than before. This is as true for companies funded by friends and family as it is for those that have venture capital backing.

If a biotech is looking to trade on major exchanges such as Nasdaq or the New York Stock Exchange (NYSE), it is important to understand that there are a variety of challenges that emerge based on the avenues taken to ensure the funding necessary to then enter the public markets. Biotechs, in particular, may want to be mindful of the ramifications of the avenue they choose.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader